OnKure Q4 2024 net loss $17.4M; cash $110.8M; PIKture-01 data in H2 2025

OnKure Therapeutics, Inc.

Net loss Q4 2024 $17.4M ($1.37/share) vs $9.5M ($30.14/share) in Q4 2023; R&D expense rose $5.6M.
Cash and equivalents $110.8M; expected to fund operations into Q4 2026 through multiple clinical readouts.
PIKture-01 Part A monotherapy enrollment near complete; PK and preliminary efficacy data expected H2 2025.
Part B fulvestrant combination dosing initiated through 900 mg BID cohort; initial data due H2 2025.
Pan-mutant PI3Kα development candidate to be announced in Q2 2025; aims for ~10x selectivity over wild type.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.